Company intelligence / Profile preview

Kimer Med

Nelson, Nelson Region, New Zealandkimermed.co.nz ↗

Ownership: Private
Development stage: Preclinical

Overview

Kimer Med has demonstrated in vitro efficacy against 21 different viruses across nine virus families and positive early in vivo data confirming efficacy and low toxicity. The lead candidate targets Dengue fever, with first significant revenue projected for 2028. The company plans to out-license its lead after successful Phase 1 trials[2][1].

Therapeutic areas: Infectious Diseases
Modalities: Recombinant proteinsBroad-spectrum antivirals[5][1]
Industry: Biotech

Drug pipeline

1 asset

VTose

Preclinical

Partnerships

Battelle Memorial Institute / US Defense Threat Reduction Agency for alphavirus program development contract ($750k USD)[4]

Beyond the preview

Go deeper on Kimer Med.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kimer Med.

Explore the full profile